Baseline tumour size is an independent prognostic factor for overall survival in PD-L1 ≥ 50% non-small cell lung cancer patients treated with first-line pembrolizumab

被引：0
|
作者：
Mathilde Bureau
Thierry Chatellier
Tanguy Perennec
Thomas Goronflot
Charlotte Greilsamer
Anne-Laure Chene
Raafet Affi
Eric Frampas
Jaafar Bennouna
Elvire Pons-Tostivint
机构：
[1] University Hospital of Nantes,Medical Oncology Unit, Hôpital Laennec, CHU de Nantes
[2] Medical Oncology Unit,Department of Radiation Oncology
[3] Institut de Cancerologie de L’Ouest,INSERM
[4] University Hospital of Nantes,Pneumology Unit
[5] Medical Oncology Unit,Radiology Unit
[6] University Hospital of Nantes,undefined
[7] University Hospital of Nantes,undefined
[8] INSERM,undefined
[9] CRCINA,undefined
来源：
Cancer Immunology, Immunotherapy | 2022年 / 71卷
关键词：
Baseline tumour size; Non-small cell lung cancer; Immune checkpoint inhibitor; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1747 / 1756
页数：9
相关论文
共 50 条
  • [21] Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features
    Passaro, Antonio
    Novello, Silvia
    Giannarelli, Diana
    Bria, Emilio
    Galetta, Domenico
    Gelibter, Alain
    Reale, Maria Lucia
    Carnio, Simona
    Vita, Emanuele
    Stefani, Alessio
    Pizzutilo, Pamela
    Stati, Valeria
    Attili, Ilaria
    de Marinis, Filippo
    CANCERS, 2021, 13 (12)
  • [22] Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Li, Qiu
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 344 - 349
  • [23] Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
    Hélène Doubre
    Laurent Greillier
    Grégoire Justeau
    Charles Ricordel
    Aurélie Swalduz
    Hubert Curcio
    Olivier Bylicki
    Jean-Bernard Auliac
    Florian Guisier
    Laurence Bigay-Game
    Marie Bernardi
    Julian Pinsolle
    Karim Amrane
    Chantal Decroisette
    Renaud Descourt
    Christos Chouaid
    Margaux Geier
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 15095 - 15102
  • [24] Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer
    Doubre, Helene
    Greillier, Laurent
    Justeau, Gregoire
    Ricordel, Charles
    Swalduz, Aurelie
    Curcio, Hubert
    Bylicki, Olivier
    Auliac, Jean-Bernard
    Guisier, Florian
    Bigay-Game, Laurence
    Bernardi, Marie
    Pinsolle, Julian
    Amrane, Karim
    Decroisette, Chantal
    Descourt, Renaud
    Chouaid, Christos
    Geier, Margaux
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (16) : 15095 - 15102
  • [25] Pembrolizumab for the first-line treatment of non-small cell lung cancer
    Ninomiya, Kiichiro
    Hotta, Katsuyuki
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (10) : 1015 - 1021
  • [26] Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer
    Shah, Mohsin
    Marmarelis, Melina E.
    Mamtani, Ronac
    Hennessy, Sean
    CLINICAL LUNG CANCER, 2022, 23 (08) : 731 - 736
  • [27] The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
    Banna, G. L.
    Cortellini, A.
    Cortinovis, D. L.
    Tiseo, M.
    Aerts, J. G. J., V
    Barbieri, F.
    Giusti, R.
    Bria, E.
    Grossi, F.
    Pizzutilo, P.
    Berardi, R.
    Morabito, A.
    Genova, C.
    Mazzoni, F.
    Di Noia, V
    Signorelli, D.
    Gelibter, A.
    Macerelli, M.
    Rastelli, F.
    Chiari, R.
    Rocco, D.
    Gori, S.
    De Tursi, M.
    Di Marino, P.
    Mansueto, G.
    Zoratto, F.
    Filetti, M.
    Montrone, M.
    Citarella, F.
    Marco, R.
    Cantini, L.
    Nigro, O.
    D'Argento, E.
    Buti, S.
    Minuti, G.
    Landi, L.
    Guaitoli, G.
    Lo Russo, G.
    De Toma, A.
    Donisi, C.
    Friedlaender, A.
    De Giglio, A.
    Metro, G.
    Porzio, G.
    Ficorella, C.
    Addeo, A.
    ESMO OPEN, 2021, 6 (02)
  • [28] Advanced non-small cell lung cancer with PD-L1≥50%: Pembrolizumab alone or combined with chemotherapy
    Han, B.
    Han, B.
    Zhang, B.
    Hu, M.
    Wang, Y.
    Yang, Z.
    Zhang, W.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S758 - S759
  • [29] Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab
    Friedlaender, Alex
    Metro, Giulio
    Signorelli, Diego
    Gili, Alessio
    Economopoulou, Panagiota
    Roila, Fausto
    Banna, Giuseppe
    De Toma, Alessandro
    Camerini, Andrea
    Christopoulou, Athina
    Lo Russo, Giuseppe
    Banini, Marco
    Galetta, Domenico
    Jimenez, Beatriz
    Collazo-Lorduy, Ana
    Calles, Antonio
    Baxevanos, Panagiotis
    Linardou, Helena
    Kosmidis, Paris
    Mountzios, Giannis
    Garassino, Marina C.
    Addeo, Alfredo
    ACTA ONCOLOGICA, 2020, 59 (09) : 1058 - 1063
  • [30] Peripheral inflammatory factors as prognostic predictors for first-line PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer
    Jin, Chen-xing
    Liu, Yan-song
    Qin, He-nan
    Teng, Yi-bin
    Sun, Rui
    Ma, Zhong-jing
    Wang, A-man
    Liu, Ji-wei
    SCIENTIFIC REPORTS, 2025, 15 (01):
12345